Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities
- PMID: 36890105
- DOI: 10.1016/j.euo.2023.02.011
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities
Abstract
Context: Bladder cancer (BLCA) is a highly prevalent tumour and a health problem worldwide, especially among men. Recent work has highlighted the relevance of the tumour microenvironment (TME) in cancer biology with translational implications. Cancer-associated fibroblasts (CAFs) are a prominent, heterogeneous population of cells in the TME. CAFs have been associated with tumour development, progression, and poor prognosis in several neoplasms. However, their role in BLCA has not yet been exploited deeply.
Objective: To review the role of CAFs in BLCA biology and provide an understanding of CAF origin, subtypes, markers, and phenotypic and functional characteristics to improve patient management.
Evidence acquisition: A PubMed search was performed to review manuscripts published using the terms "cancer associated fibroblast" and "bladder cancer" or "urothelial cancer". All abstracts were reviewed, and the full content of all relevant manuscripts was analysed. In addition, selected manuscripts on CAFs in other tumours were considered.
Evidence synthesis: CAFs have been studied less extensively in BLCA than in other tumours. Thanks to new techniques, such as single-cell RNA-seq and spatial transcriptomics, it is now possible to accurately map and molecularly define the phenotype of fibroblasts in normal bladder and BLCA. Bulk transcriptomic analyses have revealed the existence of subtypes among both non-muscle-invasive and muscle-invasive BLCA; these subtypes display distinct features regarding their CAF content. We provide a higher-resolution map of the phenotypic diversity of CAFs in these tumour subtypes. Preclinical studies and recent promising clinical trials leverage on this knowledge through the combined targeting of CAFs or their effectors and the immune microenvironment.
Conclusions: Current knowledge of BLCA CAFs and the TME is being increasingly applied to improve BLCA therapy. There is a need to acquire a deeper understanding of CAF biology in BLCA.
Patient summary: Tumour cells are surrounded by nontumoural cells that contribute to the determination of the behaviour of cancers. Among them are cancer-associated fibroblasts. The "neighbourhoods" established through these cellular interactions can now be studied with much greater resolution. Understanding these features of tumours will contribute to the designing of more effective therapies, especially in relationship to bladder cancer immunotherapy.
Keywords: Bladder cancer; Chemotherapy; Fibroblasts; Immune checkpoint inhibitors; Immunotherapy; Molecular subtypes; Signatures; Single-cell RNA-seq; Tumour microenvironment; Urothelial carcinoma.
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Comment in
-
Cancer Associated Fibroblasts: An Understudied but Critical Component of the Tumor Microenvironment in Urothelial Cancer.Eur Urol Oncol. 2023 Aug;6(4):376-377. doi: 10.1016/j.euo.2023.05.005. Epub 2023 Jun 1. Eur Urol Oncol. 2023. PMID: 37268449 Free PMC article. No abstract available.
Similar articles
-
Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression.J Cell Physiol. 2021 Feb;236(2):1321-1331. doi: 10.1002/jcp.29939. Epub 2020 Jul 13. J Cell Physiol. 2021. PMID: 32657439
-
Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study.Int J Surg. 2024 Aug 1;110(8):4911-4931. doi: 10.1097/JS9.0000000000001516. Int J Surg. 2024. PMID: 38759695 Free PMC article.
-
Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.Arch Med Res. 2024 Jan;55(1):102927. doi: 10.1016/j.arcmed.2023.102927. Epub 2023 Dec 27. Arch Med Res. 2024. PMID: 38154234
-
A review of the biology and therapeutic implications of cancer-associated fibroblasts (CAFs) in muscle-invasive bladder cancer.Front Oncol. 2022 Oct 13;12:1000888. doi: 10.3389/fonc.2022.1000888. eCollection 2022. Front Oncol. 2022. PMID: 36313650 Free PMC article. Review.
-
Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.Front Immunol. 2022 Oct 5;13:996145. doi: 10.3389/fimmu.2022.996145. eCollection 2022. Front Immunol. 2022. PMID: 36275750 Free PMC article. Review.
Cited by
-
The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways.Cell Commun Signal. 2024 Aug 19;22(1):405. doi: 10.1186/s12964-024-01776-7. Cell Commun Signal. 2024. PMID: 39160622 Free PMC article. Review.
-
Predicting the Prognosis of Bladder Cancer Patients Through Integrated Multi-omics Exploration of Chemotherapy-Related Hypoxia Genes.Mol Biotechnol. 2024 May 28. doi: 10.1007/s12033-024-01203-9. Online ahead of print. Mol Biotechnol. 2024. PMID: 38806990
-
Defining the molecular fingerprint of bladder and kidney fibroblasts.Am J Physiol Renal Physiol. 2023 Dec 1;325(6):F826-F856. doi: 10.1152/ajprenal.00284.2023. Epub 2023 Oct 12. Am J Physiol Renal Physiol. 2023. PMID: 37823192 Free PMC article. Review.
-
Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1.J Exp Clin Cancer Res. 2023 Nov 25;42(1):316. doi: 10.1186/s13046-023-02900-0. J Exp Clin Cancer Res. 2023. PMID: 38001512 Free PMC article.
-
Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells.Front Oncol. 2023 Sep 13;13:1228185. doi: 10.3389/fonc.2023.1228185. eCollection 2023. Front Oncol. 2023. PMID: 37781195 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical